Roche Diagnostics

Name

Roche Diagnostics

Legal name

Roche Diagnostics Corporation

Website

https://diagnostics.roche.com

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Roche Diagnostics is the in vitro diagnostics division of Roche Holding AG, developing IVD instruments, reagents, and digital pathology solutions for hospitals, reference laboratories, pharmaceutical companies, and patients across 150+ countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• In vitro diagnostics
• Clinical chemistry analyzers
• Molecular diagnostic systems
• Digital pathology solutions
• Immunoassay testing

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Instrumentation and Analyzers: Sale of diagnostic instruments including clinical chemistry analyzers, molecular diagnostic systems, immunoassay platforms, and digital pathology systems. Instruments provide recurring consumables revenue through reagent lock-in.
2. Consumables and Reagents: Recurring revenue from proprietary reagents, assay kits, and consumables for installed instrument base. Includes specialty reagents, control materials, and sample preparation supplies.
3. Digital Solutions and Software: Software solutions including navify portfolio for laboratory workflow management, clinical decision support, and data analytics. Revenue from software licenses, subscriptions, and platform fees.
4. Services and Support: Technical support, training, maintenance services, and laboratory optimization consulting. Includes eLabDoc document services and PACE/CEU educational programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Roche Diagnostics develops, manufactures, and sells in vitro diagnostic systems, proprietary reagents and assays, digital pathology software, and point-of-care testing devices for clinical laboratories, hospitals, and reference laboratories worldwide. The portfolio spans the cobas family of clinical chemistry and molecular analyzers, VENTANA tissue diagnostics, Elecsys immunoassays, Digital LightCycler digital PCR, Accu-Chek glucose monitoring, and the navify digital and clinical decision support platform, complemented by Foundation Medicine genomic profiling services. Revenue is anchored by instrument placements that drive recurring consumables, reagents, software subscriptions, and service contracts.

Product overview

Roche Diagnostics offers an integrated portfolio of in vitro diagnostic solutions organized around the cobas platform family for molecular and clinical chemistry testing, VENTANA for tissue diagnostics, and navify for digital pathology and clinical decision support. The core offerings include the cobas 5800/6800/8800 molecular diagnostic systems, cobas c 703 and ISE neo for clinical chemistry on the cobas pro integrated solutions platform, Digital LightCycler for digital PCR, and VENTANA automated slide staining. Digital capabilities are delivered through navify Digital Pathology (AI-powered whole-slide imaging with 20+ algorithms) and navify Algorithm Suite (cloud-based clinical decision support). Point-of-care solutions include Accu-Chek SmartGuide CGM with AI hypoglycemia prediction and CoaguChek coagulation testing. Blood-based biomarker assays include Elecsys pTau-181/pTau217 for Alzheimer's and Elecsys NfL for MS. Emerging platforms include AXELIOS 1 sequencing (SBX technology) and expanded mass spectrometry solutions. The subsidiary Foundation Medicine provides genomic profiling and MRD testing. TIB Molbiol partnership delivers over 200 LightMix research assays.

Differentiator

Problem solved

Functional benefit

Brands

• cobas: Core brand for molecular diagnostics systems including cobas 5800, cobas 6800, cobas 8800, cobas c 703, and related analyzers and assays
• VENTANA
• navify
• LightCycler
• Accu-Chek
• CoaguChek
• Elecsys
• mySugr
• Digital LightCycler
• MagNA Pure
• CustomBiotech
• KAPA
• Ionify

Products and services

• cobas 5800 System Automated molecular diagnostics system for PCR-based nucleic acid testing combining instrumentation, consumables, reagents, and data management. Compact design delivers premium performance from small footprint with assay menu including HIV, HBV, HCV, HPV, CT/NG, and transplant testing. For clinical laboratories and hospitals needing PCR testing.
• cobas 6800/8800 Systems High-throughput automated molecular diagnostic systems for centralized laboratory testing. Modular design with sample supply, transfer, processing, and analytic modules for broad menu of PCR-based tests. For high-volume reference laboratories and centralized hospital labs.
• cobas c 703 analytical unit FDA-cleared high-throughput clinical chemistry analyzer designed to double throughput on cobas pro integrated solutions with up to 2,000 tests per hour and 70 reagent positions. Features automated maintenance, intelligent continuous reagent loading with up to 6 months onboard stability, and cobas AutoCal for automatic calibration. For core laboratories.
• cobas ISE neo Ion-selective electrode analytical module for sodium, potassium, and chloride testing. Self-contained design with dedicated water, power, and reagent supplies achieving up to 1,800 tests/hour with reduced maintenance requirements. For core clinical laboratories.
• cobas pro integrated solutions Integrated clinical laboratory solution combining cobas c 703, cobas c 503, cobas e 801, and cobas ISE neo analytical units for comprehensive high-volume testing across clinical chemistry and immunoassay. For high-throughput hospital and reference laboratories.
• Digital LightCycler System Digital PCR instrument for absolute quantification of nucleic acid targets without standard curves. Features 6 fluorescence channels, 3 nanowell plate configurations (Universal 28K, High Sensitivity 20K, High Resolution 100K), and 5x concentrated master mixes for oncology, infectious disease, and transplant applications. For molecular laboratories.
• VENTANA Systems Automated slide staining systems and IHC/ISH assays for tissue-based diagnostics in oncology. Includes companion diagnostics for targeted therapy selection, biomarker testing (HER2, etc.), and AI-powered digital pathology solutions. For pathology laboratories and oncology centers.
• navify Digital Pathology AI-powered digital pathology platform for whole-slide imaging, computational diagnostics, and integrated laboratory workflows. Supports over 20 AI algorithms for cancer diagnostics and biomarker assessment. For pathology laboratories, oncology centers, and biopharma research.
• navify Algorithm Suite Cloud-based clinical decision support platform with AI algorithms integrated with hospital systems (EMR, LIS, HIS) to generate patient-centric insights, support early diagnosis of complex diseases, and improve clinical workflow efficiency. For hospitals and health systems.
• Accu-Chek SmartGuide CGM AI-driven continuous glucose monitoring system capable of predicting overnight hypoglycemia. Sensors send data every five minutes for AI-driven pattern analysis. First AI-driven device capable of predicting overnight low blood sugar episodes. For diabetes patients and endocrinologists.
• CoaguChek Systems Point-of-care coagulation testing systems for patient self-testing and professional use in monitoring anticoagulation therapy. For patients on warfarin and similar anticoagulants, anticoagulation clinics, and primary care.
• Elecsys pTau-181 FDA-cleared blood-based biomarker test measuring phosphorylated Tau 181 protein for initial assessment of Alzheimer's disease in primary care settings. First FDA-cleared blood test for ruling out Alzheimer's-related amyloid pathology with 97.9% negative predictive value. For primary care physicians, neurologists, and memory clinics.
• Elecsys pTau217 CE Mark approved blood test for detecting Alzheimer's disease pathology by measuring phosphorylated Tau 217 protein. Developed in collaboration with Eli Lilly. First blood-based assay with single-design for ruling in and ruling out amyloid pathology across primary and secondary care. For neurologists, primary care, and memory clinics.
• Elecsys NfL CE Mark approved blood test for neurofilament light chain detection in relapsing-remitting multiple sclerosis. Enables more frequent disease monitoring as complement to MRI scans. For neurologists managing MS patients.
• Ionify Steroid Assays Mass spectrometry-based steroid assays (Estradiol, DHEA, DHEA-S, Progesterone, 17-Hydroxyprogesterone, Androstenedione) for cobas i 601 analyzer. FDA categorized as CLIA 'moderate complexity' enabling routine clinical laboratory testing. For clinical laboratories running advanced diagnostic testing.
• cobas Mass Spec Solution Clinical mass spectrometry platform for advanced diagnostic testing, with cobas i 601 analyzer and an active pipeline of additional clinical mass spectrometry assays. For clinical laboratories.
• AXELIOS 1 Sequencing Platform Sequencing by expansion (SBX) technology platform featuring flexibility across read lengths on a single platform. Reduces turnaround times from days to hours. Planned for Research Use Only instrument launch with clear roadmap to clinical applications. For research and clinical sequencing laboratories.
• Foundation Medicine Roche subsidiary providing comprehensive genomic profiling, FoundationOne liquid and tissue tests, and molecular residual disease (MRD) testing for oncology. Includes Pathlight blood-based MRD platform for early breast and colorectal cancer detection following Saga Diagnostics acquisition. For oncologists and precision medicine programs.
• LightMix Assays Over 200 Life Science Research Use Only assays developed with TIB Molbiol for genetic, respiratory, pathogen, gastrointestinal, and oncology testing, distributed exclusively on LightCycler instruments. For research and esoteric diagnostic testing.
• cobas BKV Quantitative nucleic acid test for BK virus DNA in EDTA plasma and urine for management of transplant patients. Dual target assay design (VP2 and small t-Antigen) with results traceable to WHO International Standard. For transplant centers and infectious disease laboratories.

Quantifiable outcome

• 97.9% negative predictive value for Elecsys pTau181 Alzheimer's test
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development Partner · 18 May 2026Three-year MOU to advance AI-powered digital and computational pathology capabilities across nine Asia markets (Singapore, Taiwan, Korea, Thailand, Malaysia, India, Indonesia, Vietnam, Philippines), focusing on improving biomarker testing for breast and lung cancer. Studies show AI-assisted workflows can improve diagnostic accuracy by up to 5% and reclassify 24% of cases previously labelled as HER2-negative to HER2-low.
• Eli LillycoreStrategic or Co-development Partner · 12 May 2026Roche received CE Mark approval for Elecsys pTau217 blood test for detecting Alzheimer's disease pathology, developed in collaboration with Eli Lilly. The test is the first blood-based assay with a single-design intended to rule in and rule out amyloid pathology across primary and secondary care settings.
• PathAIcoreTechnology or Integration · 10 May 2026Roche announced signing of a definitive merger agreement to acquire PathAI, an AI pathology company, for $750 million upfront with additional milestone payments up to $300 million (total up to $1.05 billion), expected to close H2 2026. PathAI developed the world's first AI-driven pathological drug development tool (AIM-MASH AI Assist) certified by both FDA and EMA, and operates the Precision Pathology Network digital anatomical pathology laboratory network with 90% of top 15 global biopharma companies as customers.
• Saga DiagnosticscoreTechnology or Integration · 21 April 2026Roche agreed to acquire Saga Diagnostics for $595 million through its Foundation Medicine subsidiary. The deal enables Foundation Medicine to leverage Roche's existing sequencing and PCR platforms to develop a decentralized molecular residual disease (MRD) solution using Saga's Pathlight blood-based MRD platform, already commercialized for early breast and colorectal cancer detection.
• HNL Lab MedicinecoreStrategic or Co-development Partner · 7 April 2026Preferred partnership to enhance laboratory performance, speed, and accuracy of diagnostic results across HNL's multi-regional network in Pennsylvania. Roche's in vitro diagnostics solutions are involved in approximately 70% of healthcare decisions throughout a patient's journey. HNL processes approximately 5.6 million specimens annually through over 50 patient service centers and 31 acute care laboratories.
• Apollo HospitalscoreStrategic or Co-development Partner · 13 February 2026MoU to deploy Roche's navify Algorithm Suite, a cloud-based clinical decision support platform, integrated with Apollo's clinical systems (EMR, LIS, HIS) to generate patient-centric insights, support early diagnosis of complex diseases, and improve clinical workflow efficiency. Research and validation activities will be conducted across Apollo's innovation centers.
• Global Healthcare AcademyminorGTM or Marketing Partner · 13 February 2026Organizer of India's first national Healthcare and AI Conclave (HAI Conclave 2026) where Roche Diagnostics participated alongside Google, Philips, Siemens Healthineers, IBM, and others. Event explored how AI can improve patient care while preserving clinical judgment.
• LabcorpcoreChannel Partner/ Reseller/ Distributor · 11 February 2026Labcorp launched Roche's FDA-cleared Elecsys pTau-181 Alzheimer's blood test nationwide for primary care doctors to rule out Alzheimer's disease in patients 55 and older with cognitive decline symptoms. Test offers 97.9% negative predictive value and helps patients avoid invasive brain scans or lumbar punctures.
• TIB MolbiolcoreChannel Partner/ Reseller/ DistributorExclusive distribution partnership for LightMix and LightMix Modular assays through Roche Diagnostics. TIB Molbiol has over 20 years of partnership with Roche developing modular assays for exclusive use on LightCycler systems. Over 200 Life Science Research assays available covering genetic, respiratory, pathogen, gastrointestinal, and oncology testing areas.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Abbott Diagnostics: Abbott's diagnostics division is the second-largest global IVD player ($217.87B market cap parent), directly competing with Roche across clinical chemistry, immunoassay, molecular diagnostics, and point-of-care testing with comparable instrument-reagent recurring models.
• Siemens Healthineers: Siemens Healthineers is a major IVD competitor with the Atellica and ADVIA Centaur clinical chemistry/immunoassay platforms, directly overlapping with Roche's cobas franchise for hospital and reference laboratory customers worldwide.
• Thermo Fisher Scientific: Thermo Fisher is the third top-3 player in reagent kits (alongside Roche and Illumina), competing across clinical diagnostics, life science instruments, reagents, and specialty diagnostics with overlapping hospital and reference laboratory channels.
• Danaher (Beckman Coulter, Cepheid, Leica Biosystems): Danaher's diagnostics platforms — Beckman Coulter (clinical chemistry/immunoassay), Cepheid (molecular POC), and Leica Biosystems (tissue diagnostics) — directly compete with Roche's cobas, LightCycler, and VENTANA franchises.
• bioMérieux: bioMérieux is a global IVD specialist in microbiology and infectious disease diagnostics, directly competing with Roche's molecular infectious-disease and clinical chemistry menus in clinical laboratories.
• Hologic: Hologic competes with Roche's molecular diagnostics franchise (cobas, LightCycler) in women's health, sexually transmitted infections, and cytology, and is a key competitor in cervical cancer screening and molecular infectious-disease testing.
• Becton, Dickinson and Company (BD): BD's Diagnostic Solutions segment competes with Roche in microbiology, molecular diagnostics, and point-of-care testing, including automated blood culture and infectious-disease platforms sold to the same hospital laboratory customers.
• QIAGEN: QIAGEN is a direct competitor in molecular diagnostics — sample preparation, PCR, and NGS workflows — overlapping with Roche's MagNA Pure, LightCycler, cobas, and KAPA NGS library-prep product lines in research and clinical labs.
• Bio-Rad Laboratories: Bio-Rad is a direct IVD peer in clinical chemistry, immunoassay quality controls, blood typing, and digital PCR, with the QX600 droplet digital PCR system competing against Roche's Digital LightCycler.
• Sysmex: Sysmex is a global IVD leader in hematology and urinalysis, directly competing with Roche's hematology and point-of-care offerings and pursuing adjacent expansion into clinical chemistry and immunoassay.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/RocheDiaUSA
• YouTubeyoutube.com/user/RocheDiagnosticsUSA
• Facebookfacebook.com/RocheDiagnosticsUSA
• LinkedInlinkedin.com/showcase/roche-diagnostics-usa
• Instagraminstagram.com/rochediausa

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Diagnostics